Current Hepatitis Reports

, Volume 5, Issue 2, pp 63–67 | Cite as

Vaccination against hepatitis a and b in patients with hiv

Article
  • 24 Downloads

Abstract

Patients coinfected with HIV and viral hepatitis A or B are at increased risk for liver-related morbidity and mortality. Although vaccination is safe and effective in the general population, hepatitis A virus and hepatitis B virus transmission may continue in high-risk populations because vaccine response rates lag behind those seen in healthy populations. Poor immune response to vaccine, atypical markers of prior exposure, and difficulty reaching those at risk underlie the challenges facing clinicians and their HIV-infected patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2004, vol 16. Atlanta: US Department of Health and Human Services, CDC; 2005.Google Scholar
  2. 2.
    Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51:1–52.Google Scholar
  3. 3.
    Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286–290.PubMedCrossRefGoogle Scholar
  4. 4.
    Law WP, Duncombe CJ, Mahanontharit A, et al.: Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18:1169–1177.PubMedCrossRefGoogle Scholar
  5. 5.
    Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E: Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000, 95:1316–1322.PubMedCrossRefGoogle Scholar
  6. 6.
    Shire NJ, Rouster SD, Rajicic N, Sherman KE: Occult hepatitis B in HIV-infected patients. J Acquir Immune De.c Syndr 2004, 36:869–875.CrossRefGoogle Scholar
  7. 7.
    Dimitrakopoulos A, Takou A, Haida A, et al.: The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 2000, 40:127–131.PubMedCrossRefGoogle Scholar
  8. 8.
    Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, et al.: Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003, 50:2093–2097.PubMedGoogle Scholar
  9. 9.
    Bodsworth N, Donovan B, Nightingale BN: The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989, 160:577–582.PubMedGoogle Scholar
  10. 10.
    Hadler SC, Judson FN, O’Malley PM, et al.: Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunode efciency virus infection. J Infect Dis 1991, 163:454–459.PubMedGoogle Scholar
  11. 11.
    Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497.PubMedCrossRefGoogle Scholar
  12. 12.
    Thio CL, Seaberg EC, Skolasky R, Jr, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921–1926.PubMedCrossRefGoogle Scholar
  13. 13.
    Bessesen M, Ives D, Condreay L, et al.: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28:1032–1035.PubMedGoogle Scholar
  14. 14.
    Centers for Disease Control and Prevention: Recommended adult immunization schedule—United States, October 2005-September 2006. MMWR 2005, 54:Q1–Q4.Google Scholar
  15. 15.
    Masur H, Kaplan JE, Holmes KK: Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002, 137:435–478.PubMedGoogle Scholar
  16. 16.
    Santagostino E, Gringeri A, Rocino A, et al.: Patterns of immunogenicity of an inactivated hepatitis A vaccine in anti-HIV positive and negative hemophilic patients. Thromb Haemost 1994, 72:508–510.PubMedGoogle Scholar
  17. 17.
    Hess G, Clemens R, Bienzle U, et al.: Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995, 46:40–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Tilzey AJ, Palmer SJ, Harrington C, O’Doherty MJ: Hepatitis A vaccine responses in HIV-positive persons with haemophilia. Vaccine 1996, 14:1039–1041.PubMedCrossRefGoogle Scholar
  19. 19.
    Neilsen GA, Bodsworth NJ, Watts N: Response to hepatitis A vaccination in human immunodeficiency virusinfected and-uninfected homosexual men. J Infect Dis 1997, 176:1064–1067.PubMedCrossRefGoogle Scholar
  20. 20.
    Wallace MR, Brandt CJ, Earhart KC, et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207–1213.PubMedCrossRefGoogle Scholar
  21. 21.
    Valdez H, Smith KY, Landay A, et al.: Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Kemper CA, Haubrich R, Frank I, et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003, 187:1327–1331.PubMedCrossRefGoogle Scholar
  23. 23.
    Weissman S, Feucht C, Yarmohammadi H: Response to hepatitis A vaccination in HIV-positive patients [poster]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco: Foundation for Retrovirology and Human Health; 2004:375. Poster 830.Google Scholar
  24. 24.
    Shire NJ, Welge JA, Sherman KE: Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical Bayesian meta-analysis. Vaccine 2006, 24:272–279. Several studies have reported response rates to hepatitis A vaccine in HIV-infected patients approaching those in healthy volunteers; however, other studies have yielded a significantly abrogated rate of response in those with HIV. This random effects meta-analysis calculated an overall response rate approximating 64% by intention-to-treat analysis, underscoring the necessity of developing adjuvant immune-boosters or other methods for improving response in those with compromised immune systems.PubMedCrossRefGoogle Scholar
  25. 25.
    Overton ET, Sungkanuparph S, Powderly WG, et al.: Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045–1048.PubMedCrossRefGoogle Scholar
  26. 26.
    Gandhi RT, Wurcel A, Lee H, et al.: Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435–1441.PubMedCrossRefGoogle Scholar
  27. 27.
    Fonseca MO, Pang LW, de Paula Cavalheiro N, et al.: Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902–2908. This double-blinded, controlled, randomized trial of HBV vaccine response rates in those with HIV demonstrated that response can be improved by doubling the primary dose of vaccine but that this effect is only seen in patients with relatively well-preserved immune function (CD4+ > 350).PubMedCrossRefGoogle Scholar
  28. 28.
    Rey D, Krantz V, Partisani M, et al.: Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161–1165.PubMedCrossRefGoogle Scholar
  29. 29.
    Sasaki MG, Foccacia R, de Messias-Reason IJ: Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545–4549.PubMedCrossRefGoogle Scholar
  30. 30.
    Ahuja TS, Kumar S, Mansoury H, et al.: Hepatitis B vaccination in human immunodeficiency virus-infected adults receiving hemodialysis. Kidney Int 2005, 67:1136–1141.PubMedCrossRefGoogle Scholar
  31. 31.
    Valdez H, Mitsuyasu R, Landay A, et al.: Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003, 187:320–325.PubMedCrossRefGoogle Scholar
  32. 32.
    Bienzle U, Gunther M, Neuhaus R, et al.: Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003, 38:811–819.PubMedGoogle Scholar
  33. 33.
    Cooper CL, Davis HL, Angel JB, et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473–1479. Cooper et al. showed a statistically significant improvement in response rate to vaccine against HBV in HIV-positive patients with CPG 7909 and double dose of vaccine. At 12 months, 100% of those in the adjuvant group had achieved protective levels of antibody (versus 63% of controls).PubMedCrossRefGoogle Scholar
  34. 34.
    Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40:1–25.Google Scholar
  35. 35.
    Taylor LE, Lai A, Schwartzapfel B, et al.: Analyzing the efficacy of standard hepatitis A and B vaccination schedules in HIV/HCV co-infected patients [poster]. 10th Conference on Retroviruses and Opportunistic Infections. Boston: Foundation for Retrovirology and Human Health; 2003:338. Poster 826.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.University of CincinnatiCincinnatiUSA

Personalised recommendations